The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Optimal indications for second-line chemotherapy in advanced gastric cancer.
Hiroko Hasegawa
No relevant relationships to disclose
Kazumasa Fujitani
No relevant relationships to disclose
Shoichi Nakazuru
No relevant relationships to disclose
Motohiro Hirao
No relevant relationships to disclose
Eiji Mita
No relevant relationships to disclose
Toshimasa Tsujinaka
No relevant relationships to disclose